TT034 was an ambitious target and far too complex to cure with one treatment but the company is now pivoting to licensing its tech to other biotechs to complement their treatments. This is more tailored, targeted, cost-efficient and more likely to yield positive results.
TT034 was an ambitious target and far too complex to cure with...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
